Search

Displaying results 1311 - 1320 of 2454 in total
  1. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. ...

    Categories: P-glycoprotein inhibitors
  2. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    Ganaxolone is the 3β-methylated synthetic analog of allopregnanolone, a metabolite of progesterone. Ganaxolone belongs to a class of compounds referred to as neurosteroids. Endogenous neurosteroids, which comprise certain metabolites of ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  3. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  4. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  5. Drug

    Hepatitis B immune globulin

    go.drugbank.com/drugs/DB05276
    ApprovedInvestigational

    Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...

    Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİ
  6. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  7. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    [A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury. … Treatment options for patients with FOP are extremely limited, although there has been substantial recent interest in novel treatments for this disease.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  8. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    9-Deazaguanine

    go.drugbank.com/drugs/DB04356
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    N-Methyl-N-(Methylbenzyl)Formamide

    go.drugbank.com/drugs/DB04379
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates